Compare LVS & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LVS | WAT |
|---|---|---|
| Founded | 1988 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.2B | 33.5B |
| IPO Year | 2004 | 1996 |
| Metric | LVS | WAT |
|---|---|---|
| Price | $44.53 | $410.26 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 17 |
| Target Price | $69.21 | ★ $379.19 |
| AVG Volume (30 Days) | ★ 4.1M | 651.5K |
| Earning Date | 04-22-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | ★ 19.90 | 0.47 |
| EPS | ★ 1.38 | N/A |
| Revenue | ★ $13,017,000,000.00 | N/A |
| Revenue This Year | $7.24 | $104.66 |
| Revenue Next Year | $4.49 | $10.40 |
| P/E Ratio | $32.32 | ★ N/A |
| Revenue Growth | ★ 15.22 | N/A |
| 52 Week Low | $43.36 | $282.77 |
| 52 Week High | $70.45 | $426.22 |
| Indicator | LVS | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 42.91 | 56.25 |
| Support Level | $44.58 | $372.33 |
| Resistance Level | $54.81 | $426.22 |
| Average True Range (ATR) | 1.23 | 12.38 |
| MACD | -0.16 | -1.50 |
| Stochastic Oscillator | 29.87 | 54.10 |
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner Macao, Four Seasons Hotel Macao, and Parisian Macao, as well as the Marina Bay Sands resort in Singapore. We expect Sands to open a fourth tower in Singapore in 2031. Its Venetian and Palazzo Las Vegas assets in the US were sold to Apollo and Vici in 2022. After the sale of its Vegas assets, Sands generates all its EBITDA from Asia, with its casino operations generating the majority of sales.
Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. In early 2026, Waters merged with BD's life science and diagnostics business, which increased its concentration in diagnostics (versus none now) and discovery-related life science tools.